NCT03316274View on ClinicalTrials.gov

Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions

Kaposi SarcomaHIV/AIDSImmunosuppression

Interventions

DRUG

Nivolumab

Given via intralesional injection

Trial Locations (1)

94110

Zuckerberg San Francisco General Hospital, San Francisco

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER